CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
bit.ly/4jkdtl3
#CNSP
94
Want to follow along on our journey?
Sign up for our email alerts and never miss an update on what's ahead at CNS Pharmaceuticals.
bit.ly/4o4o0Sb
$CNSP #Oncology #Biotech #HealthcareInnovation
102
Stay up to date with $CNSP.
Sign up for email alerts to receive the latest company news, press releases and updates.
Sign up: bit.ly/4o4o0Sb
#Biotech
203
A disciplined diligence process is key when evaluating new opportunities.
$CNSP Chief Business Officer Dylan Wenke shares how the team assesses potential programs, focusing on clinical impact, commercial viability and risk as opportunities move through technical diligence.
250
#InCaseYouMissedIt
CNS Pharmaceuticals Chief Business Officer, Dylan Wenke, joined Virtual Investor for a “What This Means” segment discussing the Company’s recent asset research and what it could mean for $CNSP moving forward.
Watch here: vimeo.com/1222840808/9bb3667…
#Biotech
1
347
Follow the progress at CNS Pharmaceuticals.
Subscribe to our email alerts to receive company announcements, clinical and corporate updates, and other important news as it happens.
Sign up: bit.ly/4o4o0Sb
$CNSP #Biotech
225
CNS Pharma retweeted
$CNSP Chief Business Officer, Dylan Wenke, joins Virtual Investor’s “What This Means” series to discuss the Company’s business development strategy as it builds an oncology or neurology pipeline with best-in-class potential.
🔗 vimeo.com/1222840808/9bb3667…
@cns_pharma
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
Chief Business Officer, Dylan Wenke, Participates in Virtual Investor “What This Means” Segment
Access the segment here: bit.ly/3GplqoB
bit.ly/4xC08cE
$CNSP
236
CNS Pharma retweeted
Hope starts with pursuing what's possible.
CNS Pharmaceuticals Participates in the Virtual Investor “Why Now” On-Demand Conference
Watch the Virtual Investor Why Now Series: vimeo.com/1221551759/6f89b28…
@cns_pharma $CNSP #VirtualInvestor
CNS Pharma retweeted
Virtual Investor Launches "Why Now" On-Demand Conference Featuring Public Company CEOs
Nine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?
Access the Conference Here: virtualinvestorco.com/why-no…
$AIM $AKTX $CNSP $DARE $NVNO $ERNA $GRI
$MBRX $OTLK @AimImmuno @AkariTX @cns_pharma @DareBioscience @enVVenoMedical @ErnexaTx @GRI_BIO @moleculinbio @OutlookTx
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
Video now available here: bit.ly/4y59L3d
bit.ly/46mzW9U
$CNSP #VirtualInvestor @InvestorVirtual
Every breakthrough starts with a belief that better is possible.
At CNS Pharmaceuticals, that belief fuels our commitment to advancing innovative science and exploring new therapeutic possibilities for the future.
$CNSP #Oncology #Neurology #Biotech #HealthcareInnovation
207
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
bit.ly/4g6kljo
$CNSP #oncology #neurology
1
239
News happens fast. Stay informed.
Subscribe to CNS Pharmaceuticals email alerts for the latest company news, clinical updates, investor announcements and more.
Sign up: bit.ly/4o4o0Sb
$CNSP #Oncology #Neurology #Biotech #HealthcareInnovation
226
CEO Rami Levin will be attending the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, August 11-13.
To learn more about $CNSP and its pipeline, please contact [email protected] to schedule a meeting.
We look forward to connecting with you in Boston.
#Oncology
1
248
Want the latest updates from $CNSP delivered directly to your inbox?
Sign up for email alerts to stay informed on company news, milestones and upcoming announcements.
Subscribe here: bit.ly/4o4o0Sb
#Oncology #Neurology
202
At $CNSP, we are focused on advancing differentiated therapeutic opportunities that address significant unmet medical needs.
Guided by an experienced leadership team and a disciplined strategy, we remain committed to improving patient outcomes and creating long-term value.
2
185
In the latest CEO Connect segment, $CNSP CEO Rami Levin discusses the Company's strategic transformation, recent $22.5 million financing and efforts to build a differentiated pipeline focused on high-value opportunities.
See here: vimeo.com/1193965352/6cf0543…
#Oncology #Neurology
1
1
222
As America celebrates 250 years of independence, we wish everyone a safe and happy Fourth of July.
From all of us here at $CNSP, have a wonderful holiday.
#IndependenceDay
1
150















